Biovica
Uppsala
About Biovica
Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum™ assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality. Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum™ is CE-labeled and MPA-registered.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $17.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2025)
- Ticker: sto:BIOVIC-B
- Website: biovica.com
- Phone: +46 (0) 18 44 44 830
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/biovica-51884 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.